ZARZA We are Zarza, the prestigious firm behind major projects in information technology.

The Beacon

The Beacon

Por: H. Jack West, MD

Dr. Jack West reviews emerging new information and controversial topics in health care in general, cancer treatment in particular.

75 episodios disponibles

Latest episodes of the podcast The Beacon

Mostrando página 3 de 4

Are Tumor Mutation Burden and Nivolumab/Ipilimumab Ready for Clinical Use? Insights from CheckMate 227 (BMIC-035) 11/05/2018

Nivolumab/Ipilimumab vs. Chemo in High TMB Advanced NSCLC: Key Results from CheckMate 227 (BMIC-034) 10/05/2018

KEYNOTE-189: Clinical Implications in Patients with Advanced Non-Squamous NSCLC and Negative (sub 1%) Tumor PD-L1 Expression (BMIC-033) 04/05/2018

KEYNOTE-189: Clinical Implications in Patients with Advanced Non-Squamous NSCLC and Low (1-49%) Tumor PD-L1 Expression (BMIC-032) 04/05/2018

KEYNOTE-189: Clinical Implications in Patients with Advanced Non-Squamous NSCLC and High (≥50%) Tumor PD-L1 Expression (BMIC-031) 30/04/2018

KEYNOTE-189: Key Summary of a Practice-Changing Trial in Advanced Non-Squamous NSCLC (BMIC-030) 27/04/2018

Is Chemotherapy More Effective After Prior Immunotherapy? (BMIC-029) 12/04/2018

New Insights on Acquired Resistance to Immune Checkpoint Inhibitors for NSCLC: Implications for Treatment Options (BMIC-028) 10/04/2018

Is immunotherapy ineffective in patients with driver mutation-positive advanced NSCLC? Time to walk that back. (BMIC-027) 06/04/2018

Chemo/Immunotherapy in Advanced Squamous NSCLC: What is the Impact of IMpower131? (BMIC-026) 04/04/2018

Is Durvalumab (Imfinzi) in Stage III NSCLC Curing Patients or Just Treating Metastatic Disease Earlier? Importance of Overall Survival and Implications for Duration of Treatment (BMIC-025) 22/02/2018

Durvalumab (Imfinzi) FDA Approved for Stage III NSCLC: Should It Become Standard of Care Without Overall Survival Benefit Demonstrated? (BMIC-024) 20/02/2018

A New Treatment Option for Uncommon EGFR Mutations (BMIC-023) 22/01/2018

Chemo-Immunotherapy in Non-Squamous NSCLC: Has the KEYNOTE-189 Trial Defined a Clear Standard of Care? (BMIC-022) 20/01/2018

T Effector Gene Signature on IMpower150: Is There a Better Biomarker than PD-L1 for Immunotherapy? (BMIC-021) 21/12/2017

Atezolizumab in First Line NSCLC: Early Clinical Results from the IMpower150 Trial (BMIC-020) 18/12/2017

Genomic Sequencing for All Solid Tumors: Where Will This Lead Us? (BMIC-019) 11/12/2017

New Target & Treatment in Advanced NSCLC: Dabrafenib/Trametinib for BRAF V600E Mutation-Positive NSCLC (BMIC-018) 08/12/2017

Should Osimertinib Become First-Line Treatment of Choice for EGFR Mutation-Positive Advanced NSCLC, or Should it Be Saved for Later? (BMIC-017) 01/12/2017

Dacomitinib: Dark Horse EGFR TKI Charges into a Crowded First Line Setting for EGFR Mutation-Positive Advanced NSCLC (BMIC-016) 28/11/2017

« Primera ‹ Anterior 1 2 3 4 Siguiente › Última »